

Anxiolytics

Point-of-Sale (POS) edits are safety limitations that are automatically verified through computer programming at the time that a prescription claim is submitted at the pharmacy. These edits can be applied to *any* medication, whether or not it is listed in the Preferred Drug List / Non-Preferred Drug List (PDL/NPDL). The first section of this document is organized to follow the order of the therapeutic classes in the PDL/NPDL and explains the POS edits for those medications.

POS Abbreviations

AL – Age Limit	DD – Drug-Drug Interaction	MD – Maximum Dose Limit	TD - Therapeutic Duplication
BH – Behavioral Health Clinical Authorization for Children Younger than 7 Years of Age	DS Maximum Days’ Supply Allowed	PR – Enrollment in a Physician-Supervised Program Required	UN – Drug Use Not Warranted
BY – Diagnosis Codes Bypass Some Requirements	DT – Duration of Therapy Limit	PU – Prior Use of Other Medication is Required	X – Prescriber Must Have ‘X’ DEA Number
CL – Additional Clinical Information is Required	DX – Diagnosis Code Requirement	QL – Quantity Limit	YQ – Yearly Quantity Limit
CU – Concurrent Use with Other Medication is Restricted	ER – Early Refill	RX – Specific Prescription Requirement	

Pharmacy Prior Authorization Phone Numbers for MCOs and FFS

Aetna Better Health of Louisiana **1-855-242-0802**

AmeriHealth Caritas Louisiana **1-800-684-5502**

Fee-for-Service (FFS) Louisiana Legacy Medicaid **1-866-730-4357**

Healthy Blue **1-844-521-6942**

Louisiana Healthcare Connections **1-888-929-3790**

UnitedHealthcare **1-800-310-6826**

Anxiolytics

POS Edits

AL – Alprazolam XR and alprazolam ODT are limited to use in recipients who are at least 18 years of age.

BH – Additional behavioral-health related clinical information (trial of behavioral therapy, etc.) is required for all agents, **EXCEPT** meprobamate, when requested for recipients who are younger than 7 years of age.

BY – Pharmacy claims for selected anxiolytics, when submitted with a seizure-related diagnosis code will bypass the behavioral-health clinical authorization requirement, the restriction on concurrent use with opioids, and quantity limits (see Anxiolytic Quantity Limits *with* Bypass Diagnosis Codes chart below).

CU – Benzodiazepines are monitored at POS for concurrent use with opioids and buprenorphine-containing products.

- Concurrent pharmacy claims for benzodiazepines and buprenorphine will deny.
- Incoming benzodiazepine pharmacy claims will deny when the recipient has an active prescription (a prescription in which the days' supply has not expired) for an opioid.

DX – Pharmacy claims for alprazolam ER and alprazolam ODT require an appropriate diagnosis code found at [THIS LINK](#).

QL – Solid oral dosage forms have quantity limits. A diagnosis code bypass is available for some agents as listed in the charts to the right.	Anxiolytic Quantity Limits <i>with</i> Bypass Diagnosis Codes	
	Generic (Brand Example)	Quantity Limit
	Clonazepam (Klonopin®)	90 units in 30 days
	Clorazepate (Tranxene T-Tab®)	90 units in 30 days
	Diazepam (Valium®)	90 units in 30 days
	Lorazepam (Ativan®) Injectable	No Quantity Limit Applicable
	Seizure-Related Diagnosis Codes Will Bypass Behavioral Health Clinical Authorization Requirement or Concurrent Use with Opioids or Applicable Quantity Limits	Epilepsy, Seizures G40.*
		Convulsions in Newborn P90
		Other Convulsions R56.*
	* Any number or letter or combination of UP TO FOUR numbers and letters of an assigned ICD-10-CM code	
	Anxiolytic Quantity Limits <i>without</i> Bypass Diagnosis Codes	
	Generic (Brand Example)	Quantity Limit
	Alprazolam ER (Xanax XR®)	30 units in 30 days
	Alprazolam (Xanax®)	90 units in 30 days
	Chlordiazepoxide (Librium®)	90 units in 30 days
	Lorazepam (Ativan®)	90 units in 30 days
	Oxazepam	90 units in 30 days

TD – These agents are monitored at the pharmacy POS for duplication of therapy with each other and with oxybate (Xyrem®).

Anxiolytics

Revision / Date	Implementation Date
Created POS Document	February 2020
Modified to apply new age requirement for behavioral health clinical authorization / September 2020	January 2021